Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of HR19042 Capsules in Healthy Subjects
NCT06922305Phase 1Completed
- Sponsor
- Hengrui
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR19042 in IgA nephropathy (IgAN) and autoimmune hepatitis (AIH) (6 arms), sponsored by Hengrui. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and 2 more. Started Dec 2023; status: completed.
02
Drugs
HR19042
03
Conditions
IgA nephropathy (IgAN)autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT06922305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922305.